<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005246" GROUP_ID="PROSTATE" ID="165203110315015329" MERGED_FROM="" MODIFIED="2012-01-17 17:33:31 +0100" MODIFIED_BY="James Tacklind" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-01-17 10:32:17 -0600" NOTES_MODIFIED_BY="James Tacklind" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2012-01-17 17:33:31 +0100" MODIFIED_BY="James Tacklind">
<TITLE MODIFIED="2012-01-17 10:30:12 -0600" MODIFIED_BY="James Tacklind">Neo-adjuvant chemotherapy for invasive bladder cancer</TITLE>
<CONTACT MODIFIED="2012-01-17 17:33:31 +0100" MODIFIED_BY="James Tacklind"><PERSON ID="E456BADB82E26AA201E74FE959393E8B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Claire</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Vale</LAST_NAME><POSITION>Senior Research Scientist</POSITION><EMAIL_1>cv@ctu.mrc.ac.uk</EMAIL_1><EMAIL_2>Hidden</EMAIL_2><MOBILE_PHONE>Hidden</MOBILE_PHONE><ADDRESS><DEPARTMENT>Meta-analysis Group</DEPARTMENT><ORGANISATION>MRC Clinical Trials Unit</ORGANISATION><ADDRESS_1>Aviation House</ADDRESS_1><ADDRESS_2>125 Kingsway</ADDRESS_2><CITY>London</CITY><ZIP>WC2B 6SE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7670 4723</PHONE_1><PHONE_2>+44 20 7670 4700</PHONE_2><FAX_1>+44 20 7670 4816</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-01-17 17:33:31 +0100" MODIFIED_BY="James Tacklind"><GROUP ID="30DDF3A682E26AA20139CB72DC6DAC44"><GROUP_NAME>Advanced Bladder Cancer Meta-analysis Collaboration</GROUP_NAME><ADDRESS><DEPARTMENT>MRC Clinical Trials Unit</DEPARTMENT><ORGANISATION/><ADDRESS_1>222 Euston Road</ADDRESS_1><CITY>London</CITY><ZIP>NW1 2DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></GROUP></CREATORS>
<DATES MODIFIED="2008-05-29 08:14:44 -0500" MODIFIED_BY="Jim Tacklind">
<UP_TO_DATE>
<DATE DAY="3" MONTH="11" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="11" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-17 10:30:30 -0600" MODIFIED_BY="James Tacklind">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-17 10:30:30 -0600" MODIFIED_BY="James Tacklind">
<DATE DAY="17" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Added grant info.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-01-17 10:30:18 -0600" MODIFIED_BY="James Tacklind">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-17 10:30:18 -0600" MODIFIED_BY="James Tacklind">
<DATE DAY="29" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="3" MONTH="11" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-01-17 10:32:17 -0600" MODIFIED_BY="James Tacklind">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-01-17 10:32:17 -0600" MODIFIED_BY="James Tacklind">
<SOURCE MODIFIED="2012-01-17 10:32:17 -0600" MODIFIED_BY="James Tacklind">
<NAME>Grant no. 5R01DK63300-4</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editing support was in part provided by the National Institutes of Health (NIH), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-01-15 04:35:35 -0600" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-06-09 13:09:19 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-06-09 13:06:27 -0500" MODIFIED_BY="[Empty name]">Adding chemotherapy before surgery and/or radiotherapy in patients with invasive bladder cancer.</TITLE>
<SUMMARY_BODY MODIFIED="2008-06-09 13:09:19 -0500" MODIFIED_BY="[Empty name]">
<P>The standard treatment for invasive bladder cancer is surgery (to remove the bladder and surrounding tissues), and/or radiotherapy (to kill the cancer cells). This review suggests that 50 out of 100 patients will be alive at five years, when they are given chemotherapy using a platinum drug in combination with other drugs, before having surgery and/or radiotherapy. This is compared to 45 out of every 100 patients who were given surgery and/or radiotherapy without chemotherapy. This benefit of platinum-based combination chemotherapy was seen in all types of patients and encourages its use for the treatment of invasive bladder cancer. However, chemotherapy based on a single platinum drug did not help patients live longer, and is not recommended.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-29 10:32:27 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials (RCTs) involving over 3000 patients. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To conduct a systematic review and meta-analysis of individual patient data to evaluate the effect of neoadjuvant chemotherapy on survival in patients with this invasive bladder cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>MEDLINE and Cancerlit searches were supplemented with information from registers and by hand searching meeting proceedings and also by discussion with relevant trialists and organisations. These have been regularly updated until June 2003.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-05-29 10:28:04 -0500" MODIFIED_BY="[Empty name]">
<P>Trials that aimed to randomise patients with biopsy proven invasive (i.e. clinical stage T2 to T4a) transitional cell carcinoma of the bladder to receive local definitive treatment with or without neoadjuvant chemotherapy were eligible for inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We collected, validated and re-analysed updated data on all randomised patients from all available randomised trials, including 3005 patients from 11 RCTs. For all outcomes, we obtained overall pooled hazard ratios using the fixed effects model. To explore the potential impact of trial design we pre-planned analyses that grouped trials by important aspects of their design that might influence the treatment effect. To investigate any differences in effect by pre-defined patient subgroups we used a stratified logrank analysis on the primary endpoint of survival.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-05-29 10:32:27 -0500" MODIFIED_BY="[Empty name]">
<P>These results include data from one extra trial and so update those in the original publication ABC 2003. Platinum based combination chemotherapy showed a significant benefit on overall survival with a combined hazard ratio (HR) 0.86 (95% CI 0.77 to 0.95, P = 0.003); 14% reduction in the risk of death; 5% absolute benefit at 5 years (95% CI 1% to 7%); overall survival increased from 45% to 50%. This effect was observed irrespective of the type of local treatment and did not vary between subgroups of patients. The HR for all trials, including those that used single-agent cisplatin, tended to favour neoadjuvant chemotherapy (HR= 0.89, 95% CI 0.81 to 0.98, P = 0.022). Although platinum based combination chemotherapy was beneficial, there was no clear evidence to support the use of single-agent platinum, indeed there was significant difference in the effect between these groups of trials (P = 0.029).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>This improvement in survival encourages the use of platinum based combination chemotherapy for patients with invasive bladder cancer.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-01-15 04:35:35 -0600" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-01-15 04:35:35 -0600" MODIFIED_BY="[Empty name]">
<P>Bladder cancer is the second most common cancer of the genito-urinary system; 80% of all cases are in men. Worldwide estimates suggest that the frequency of bladder cancer is about 336,000 new cases per year (<LINK REF="REF-Parkin-1999" TYPE="REFERENCE">Parkin 1999</LINK>), of which about a third are likely to be invasive or metastatic disease.</P>
<P>Neoadjuvant chemotherapy, given before local treatment, may reduce primary tumour volume and could be effective in the control of metastatic disease when the volume of micrometastases is likely to be small (<LINK REF="REF-Soloway-1981" TYPE="REFERENCE">Soloway 1981</LINK>; <LINK REF="REF-Fagg-1984" TYPE="REFERENCE">Fagg 1984</LINK>; <LINK REF="REF-Raghavan-1984" TYPE="REFERENCE">Raghavan 1984</LINK>). This could be important since about half of the patients who present with invasive disease are likely to have occult metastases. Furthermore, patients may best tolerate chemotherapy before they have received potentially debilitating local treatment with either surgery or radiotherapy. Local treatments may also affect drug delivery by altering blood supply especially to the tissues affected by the tumour (<LINK REF="REF-Martinez-1998" TYPE="REFERENCE">Martinez 1998</LINK>). Therefore, neoadjuvant chemotherapy has the potential to deliver the drugs more efficiently and at higher doses than in the adjuvant setting and provides an opportunity to prospectively assess the response to chemotherapy.</P>
<P>Several randomised trials, most of which have included platinum-based regimens (<LINK REF="STD-Abol_x002d_Enein-1997" TYPE="STUDY">Abol-Enein 1997</LINK>; <LINK REF="STD-MRC_x002f_EORTC-1999" TYPE="STUDY">MRC/EORTC 1999</LINK>; <LINK REF="STD-Bassi-1999" TYPE="STUDY">Bassi 1999</LINK>; <LINK REF="STD-Cortesi-_x0028_unpub_x0029_" TYPE="STUDY">Cortesi (unpub)</LINK>; <LINK REF="STD-Malmstrom-1996" TYPE="STUDY">Malmstrom 1996</LINK>; <LINK REF="STD-Martinez-1995" TYPE="STUDY">Martinez 1995</LINK>; <LINK REF="STD-Raghavan-1991" TYPE="STUDY">Raghavan 1991</LINK>; <LINK REF="STD-Sengelov-2002" TYPE="STUDY">Sengelov 2002</LINK>; <LINK REF="STD-Shearer-1988" TYPE="STUDY">Shearer 1988</LINK>; <LINK REF="STD-Sherif-2002" TYPE="STUDY">Sherif 2002</LINK>; <LINK REF="STD-Grossman-2003" TYPE="STUDY">Grossman 2003</LINK>) have been done to investigate the use of neoadjuvant chemotherapy. These trials, which have been undertaken over almost twenty years, have mostly been of modest size and shown inconclusive results. However, combining the results of all of the relevant randomised trials in a meta-analysis could provide sufficient evidence and increase the statistical power to reliably assess the value of neoadjuvant chemotherapy in the treatment of invasive bladder cancer. In 1991, we initiated and coordinated a systematic review and meta-analysis of individual patient data from all of the existing trials that compared local definitive treatment with or without neoadjuvant systemic chemotherapy (<LINK REF="REF-ABCOC-1995" TYPE="REFERENCE">ABCOC 1995</LINK>). At that time, only four trials, including less than 500 patients, were available The results showed no clear evidence of either benefit or harm from the treatment and it was concluded that further large-scale randomised evidence was necessary. Subsequent systematic reviews and meta-analyses based on summary data extracted from trial reports have been of limited value, because of their methodological limitations and because only a subset of the trials were published at the time (<LINK REF="REF-Parmar-1999" TYPE="REFERENCE">Parmar 1999</LINK>; <LINK REF="REF-Sternberg-2001" TYPE="REFERENCE">Sternberg 2001</LINK>). No good evidence existed to suggest that neoadjuvant chemotherapy, with either cisplatin alone, or in combination with other agents, improved survival in this group of patients.</P>
<P>We therefore initiated a new systematic review and meta-analysis of individual patient data to build on the previous project and to collect, validate and re-analyse trial data on all randomised patients from all relevant trials. Use of data from individual patients has many advantages in such a meta-analysis (<LINK REF="REF-Stewart-1995" TYPE="REFERENCE">Stewart 1995</LINK>). In particular, such data permit time-to-event analyses, which are extremely important in diseases where prolongation of survival, rather than cure, is anticipated for most patients. They also allow analyses to assess whether chemotherapy is more or less effective in different subgroups of patients. Importantly, there is evidence from the cancer field that meta-analyses based on data extracted from published reports can give different results from those based on updated individual patient data (<LINK REF="REF-AOCTG-1991" TYPE="REFERENCE">AOCTG 1991</LINK>; <LINK REF="REF-Stewart-1993" TYPE="REFERENCE">Stewart 1993</LINK>; <LINK REF="REF-Clarke-1998" TYPE="REFERENCE">Clarke 1998</LINK>). Our meta-analysis was initiated and coordinated by the Medical Research Council (UK) Clinical Trials Unit.</P>
</BACKGROUND>
<OBJECTIVES>
<P>This meta-analysis forms the main part of a broader project looking at the effect of chemotherapy given in three different ways in invasive bladder cancer: (1) before local treatment (neoadjuvant); (2) during local treatment (concurrent) and (3) after local treatment (adjuvant). We followed a detailed prespecified protocol, which defines the objectives, inclusion criteria for trials, data to be obtained, and analyses to be done. A copy of the trial protocol is available on request. In the first part of the project we aimed to assess the effect of neoadjuvant chemotherapy plus standard local treatment (radical cystectomy, radical radiotherapy or preoperative radiotherapy plus cystectomy) versus the same local treatment alone. We also aimed to compare the effect of concurrent chemoradiotherapy plus local treatment with that of the same local treatment alone. Work is continuing on the separate question of adjuvant chemotherapy and results will be presented in due course. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-05-29 12:24:40 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-05-29 12:24:40 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>To be included in the meta-analysis, trials had to be properly randomised and should have been closed to patient accrual at the time of the final data collation.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-05-29 10:51:02 -0500" MODIFIED_BY="[Empty name]">
<P>Trials should have aimed to randomise patients with biopsy proven invasive (i.e. clinical stage T2 to T4a) transitional cell carcinoma of the bladder.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Patients should have been randomised to receive local definitive treatment with or without neoadjuvant chemotherapy. The comparison had to be unconfounded by additional agents or interventions. The same local treatment should have been used on each arm, i.e. control and experimental arms had to differ only by the addition of chemotherapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-05-29 12:24:40 -0500" MODIFIED_BY="[Empty name]">
<P>The primary endpoint of overall survival was defined as the time from randomisation until death. Living patients were censored on the date of last follow up. Overall disease-free survival was defined as the time from randomisation until first recurrence or progression (after randomisation) or death, whichever happened first. Loco-regional disease-free survival was defined as the time from randomisation to first local recurrence or progression (after randomisation) or death. Metastases-free survival was defined as the time from randomisation to first metastases (after randomisation) or death. Patients alive without disease were censored on the date of last follow up. For all endpoints, death was defined as death by any cause.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-05-29 10:57:56 -0500" MODIFIED_BY="[Empty name]">
<P>To limit publication bias, both published and unpublished trials were included. We searched MEDLINEand CancerLit databases using a version of the Cochrane Collaboration optimal search strategy (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). These searches were supplemented by hand searches of the reference lists of identified trials, bibliographies of relevant books and review articles. The National Cancer Institute PDQ (Physicians Data Query) Clinical Protocols, United Kingdom Coordinating Committee for Cancer Research trials register and the Current Controlled Trials metaRegister of trials were also searched to identify unpublished and ongoing trials. All trialists who took part in the meta-analysis were asked to help to identify additional trials. Trials that had not been published in the English language were not excluded. Initial searches were completed for the period up to and including January 1st, 2001. These were revised regularly to identify any additional new material that had appeared by our final analyses in June 2004. Two reviewers independently assessed all titles identified by search strategies for relevance. Abstracts were downloaded for all titles of potential relevance, and full papers obtained for all abstracts judged potentially relevant. In cases of uncertainty about the eligibility of a trial or particular treatment arms within a trial, the matter was discussed and resolved by consensus within the project secretariat and the international advisory group.</P>
<OL>
<LI>PT=RANDOMIZED-CONTROLLED-TRIAL</LI>
<LI>RANDOMIZED-CONTROLLED-TRIAL.DE.</LI>
<LI>RANDOM-ALLOCATION.DE.</LI>
<LI>DOUBLE-BLIND-METHOD.DE.</LI>
<LI>SINGLE-BLIND-METHOD.DE.</LI>
<LI>1 OR 2 OR 3 OR 4 OR 5</LI>
<LI>PT=CLINICAL-TRIAL</LI>
<LI>CLINICAL-TRIAL#.DE.</LI>
<LI>(CLIN$ WITH TRIAL$).AB, TI.</LI>
<LI>((SINGL$ OR DOUBL$ OR TREBL$ OR TRIPL$) WITH (BLIND$ OR MASK$)).AB,TI.</LI>
<LI>PLACEBO$.DE.</LI>
<LI>PLACEBO$.AB,TI.</LI>
<LI>RANDON$.AB,TI.</LI>
<LI>RESEARCH-DESIGN.DE</LI>
<LI>7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14</LI>
<LI>CARCINOMA#.DE.</LI>
<LI>BLADDER-NEOPLASMS.DE.</LI>
<LI>BLADDER ADJ CARCINOMA$.AB,TI.</LI>
<LI>BLADDER ADJ CANCER$.AB,TI</LI>
<LI>BLADDER ADJ NEOPLASM$.AB,TI.</LI>
<LI>(CANCER WITH BALDDER).AB,TI.</LI>
<LI>(CARCINOMA WITH BLADDER).AB,TI.</LI>
<LI>16 AND 17</LI>
<LI>18 OR 19 OR 20 OR 21 OR 22</LI>
<LI>23 OR 24</LI>
<LI>DRUG-THERAPY#.DE</LI>
<LI>QS NEOPLASMS# WITH DT</LI>
<LI>26 OR 27</LI>
<LI>RADIOTHERAPY#.DE</LI>
<LI>QS NEOPLASMS# WITH RT</LI>
<LI>29 OR 30</LI>
<LI>SURGERY#.DE</LI>
<LI>QS NEOPLASMS# WITH SU</LI>
<LI>32 OR 33</LI>
<LI>28 OR 31 OR 34</LI>
<LI>SUPERFICIAL</LI>
<LI>6 OR 15</LI>
<LI>37 AND 25 AND 35</LI>
<LI>38 NOT 36</LI>
</OL>
<P>
<BR/>
</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-05-29 12:00:53 -0500" MODIFIED_BY="[Empty name]">
<P>We sought up-to-date individual patient information on date of randomisation, survival status, local recurrence status, metastases status and date of last follow up. Details of treatment allocated, age, sex, TNM category, grade, performance status, tumour diameter, renal function and pre-treatment haemoglobin were also obtained. To reduce potential bias, we requested information for all randomised patients including those who had been excluded from the investigators' original analyses. All data were thoroughly checked (<LINK REF="REF-Stewart-1995" TYPE="REFERENCE">Stewart 1995</LINK>) for consistency, plausibility and integrity of randomisation and follow up. Any queries were resolved and the final database entries verified by the responsible trial investigator or statistician.</P>
<P>Analyses of all endpoints, subsets and subgroups were pre-specified in the protocol and carried out on an intention-to-treat basis. Analyses of all of the endpoints were stratified by trial, and the log rank expected number of deaths and variance used to calculate individual trial hazard ratios and overall pooled hazard ratios (HR) using the fixed-effect model (<LINK REF="REF-Yusuf-1985" TYPE="REFERENCE">Yusuf 1985</LINK>). [NB. Hazard Ratios calculated are labelled as Peto ORs in all of the forest plots.] Thus, the times to event (recurrence, progression or death) for individual patients were used within trials to calculate the HR, representing the overall risk of an event for those patients allocated to neoadjuvant chemotherapy compared with those allocated to no chemotherapy.</P>
<P>To examine the potential impact of trial design and the treatments used, we prospectively planned analyses that grouped trials by important aspects that might influence the effect of chemotherapy. Groups were defined according to the type of the chemotherapy regimen and also by the local treatment. For each of these analyses, we calculated a pooled HR for each group of trials and for all trials together. A chi-square test for quantitative interaction was used to find out whether the effect of neoadjuvant chemotherapy differed substantially between the trial groups. These analyses focused on the primary endpoint of overall survival, however they were conducted for the other endpoints to help to support or to refute any patterns found. The effects of chemotherapy within subgroups of patients were investigated using similar stratified analyses. Analyses were performed for each pre-specified subgroup, for example, comparing treatment and control for males and for females within each individual trial. These results were then combined to give overall HRs for males and for females.</P>
<P>We also calculated absolute differences at five years, using the overall HRs and event rate on the control arm (<LINK REF="REF-Parmar-1995" TYPE="REFERENCE">Parmar 1995</LINK>). Confidence intervals for absolute differences were calculated from the baseline event rate and the HR at the 95% confidence interval boundary values. Chi<SUP>2</SUP> heterogeneity tests (<LINK REF="REF-Stewart-1995" TYPE="REFERENCE">Stewart 1995</LINK>) were used to test for statistical heterogeneity across trials. The power of this test is however acknowledged to be low and thus only gross statistical heterogeneity is likely to be detected. We used Chi-square tests for interaction or trend to test for differences in outcome between subsets of trials or between subgroups of patients. Survival curves are presented as simple (non-stratified) Kaplan-Meier curves (<LINK REF="REF-Kaplan-1958" TYPE="REFERENCE">Kaplan 1958</LINK>). All P values quoted are two-sided.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-01-15 04:35:35 -0600" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-01-15 04:35:35 -0600" MODIFIED_BY="[Empty name]">
<P>(1) Neoadjuvant Chemotherapy trials</P>
<P>We identified 14 randomised trials using neoadjuvant chemotherapy that were potentially eligible for inclusion. Three of these were subsequently found to be ineligible; one because it was confounded by the use of additional treatments in both arms (<LINK REF="STD-Ozono-1991" TYPE="STUDY">Ozono 1991</LINK>), a second because chemoradiotherapy was used as the local treatment (<LINK REF="STD-Shipley-1998" TYPE="STUDY">Shipley 1998</LINK>) and the third compared neoadjuvant with adjuvant chemotherapy (<LINK REF="STD-Millikan-2001" TYPE="STUDY">Millikan 2001</LINK>). There were therefore 11 remaining trials eligible for inclusion and data were obtained for all of these. In our original publication (<LINK REF="REF-ABC-2003" TYPE="REFERENCE">ABC 2003</LINK>), one of these trials, including a total of 317 patients, was not available because the investigators felt unable to supply data for inclusion in the meta-analysis prior to publication. This trial has now been published (<LINK REF="STD-Grossman-2003" TYPE="STUDY">Grossman 2003</LINK>) and the investigators have supplied data for inclusion in this update of the original meta-analysis.</P>
<P>Individual patient data were supplied on 3005 patients from 11 randomised controlled trials (<LINK REF="STD-Abol_x002d_Enein-1997" TYPE="STUDY">Abol-Enein 1997</LINK>; <LINK REF="STD-MRC_x002f_EORTC-1999" TYPE="STUDY">MRC/EORTC 1999</LINK>; <LINK REF="STD-Cortesi-_x0028_unpub_x0029_" TYPE="STUDY">Cortesi (unpub)</LINK>; <LINK REF="STD-Malmstrom-1996" TYPE="STUDY">Malmstrom 1996</LINK>; <LINK REF="STD-Martinez-1995" TYPE="STUDY">Martinez 1995</LINK>; <LINK REF="STD-Raghavan-1991" TYPE="STUDY">Raghavan 1991</LINK>; <LINK REF="STD-Sengelov-2002" TYPE="STUDY">Sengelov 2002</LINK>; <LINK REF="STD-Sherif-2002" TYPE="STUDY">Sherif 2002</LINK>; <LINK REF="STD-Wallace-1991" TYPE="STUDY">Wallace 1991</LINK>; <LINK REF="STD-Grossman-2003" TYPE="STUDY">Grossman 2003</LINK>) representing 98% of individuals from all known, eligible randomised trials. Data were collected for 18 of the 51 randomised patients who had been excluded from the investigators' analyses of these ten trials and were reinstated in the meta-analysis. For the available trials, patient accrual ranged from 96 to 976. In six trials (<LINK REF="STD-Martinez-1995" TYPE="STUDY">Martinez 1995</LINK>; <LINK REF="STD-Cortesi-_x0028_unpub_x0029_" TYPE="STUDY">Cortesi (unpub)</LINK>; <LINK REF="STD-Abol_x002d_Enein-1997" TYPE="STUDY">Abol-Enein 1997</LINK>; <LINK REF="STD-Bassi-1999" TYPE="STUDY">Bassi 1999</LINK>; <LINK REF="STD-Sherif-2002" TYPE="STUDY">Sherif 2002</LINK>; <LINK REF="STD-Grossman-2003" TYPE="STUDY">Grossman 2003</LINK>) the planned local treatment was radical cystectomy, two used radical radiotherapy (<LINK REF="STD-Wallace-1991" TYPE="STUDY">Wallace 1991</LINK>; <LINK REF="STD-Raghavan-1991" TYPE="STUDY">Raghavan 1991</LINK>) and one used pre-operative radiotherapy and cystectomy (<LINK REF="STD-Malmstrom-1996" TYPE="STUDY">Malmstrom 1996</LINK>). Two trials used a combination of one or more of these local treatments (<LINK REF="STD-MRC_x002f_EORTC-1999" TYPE="STUDY">MRC/EORTC 1999</LINK>; <LINK REF="STD-Sengelov-2002" TYPE="STUDY">Sengelov 2002</LINK>). All of the trials used platinum-based chemotherapy. Ten trials used cisplatin, either as a single agent (<LINK REF="STD-Martinez-1995" TYPE="STUDY">Martinez 1995</LINK>; <LINK REF="STD-Raghavan-1991" TYPE="STUDY">Raghavan 1991</LINK>; <LINK REF="STD-Wallace-1991" TYPE="STUDY">Wallace 1991</LINK> (3 trials)) or in combination with one or more of doxorubicin / epirubicin, methotrexate and vinblastine (<LINK REF="STD-MRC_x002f_EORTC-1999" TYPE="STUDY">MRC/EORTC 1999</LINK>; <LINK REF="STD-Bassi-1999" TYPE="STUDY">Bassi 1999</LINK>; <LINK REF="STD-Cortesi-_x0028_unpub_x0029_" TYPE="STUDY">Cortesi (unpub)</LINK>; <LINK REF="STD-Malmstrom-1996" TYPE="STUDY">Malmstrom 1996</LINK>; <LINK REF="STD-Sengelov-2002" TYPE="STUDY">Sengelov 2002</LINK>; <LINK REF="STD-Sherif-2002" TYPE="STUDY">Sherif 2002</LINK>; <LINK REF="STD-Grossman-2003" TYPE="STUDY">Grossman 2003</LINK> (7 trials)). Cisplatin doses ranged from 70 mg/m<SUP>2</SUP> per cycle for 2 to 4 cycles to 100 mg/m<SUP>2</SUP> per cycle given in 2 to 3 cycles, every 2 to 4 weeks. One further trial used carboplatin in combination with methotrexate and vinblastine (<LINK REF="STD-Abol_x002d_Enein-1997" TYPE="STUDY">Abol-Enein 1997</LINK>). The carboplatin dose per cycle was 300 mg/m<SUP>2</SUP> given in 2 cycles at 3-week intervals.</P>
<P>Patient characteristics, which reflect the eligibility criteria of the included trials, are given in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Age, sex and clinical T stage data were provided for all trials. Grade and performance status were supplied for eight trials, and clinical N category for seven trials. Tumour diameter and renal function (recorded as glomerular filtration rate) were supplied in full for only one trial. Pre-treatment haemoglobin data could not be supplied in full for any of the trials. Based on the available data, patients were mostly male with a median age across all trials of 63 years (range 30 to 90 years) with good performance status and tumours that were predominantly T2 to T3. The median follow up for surviving patients across all trials is 6.4 years. For one trial (<LINK REF="STD-Wallace-1991" TYPE="STUDY">Wallace 1991</LINK>), follow up could not be updated, however survival data for this trial had been included in the 1995 IPD meta-analysis conducted by the <LINK REF="REF-ABCOC-1995" TYPE="REFERENCE">ABCOC 1995</LINK>. These data were therefore included in our survival analysis. Two trials had only recorded survival and overall disease-free survival and so could not be included in the analyses of locoregional disease-free survival or metastases-free survival (<LINK REF="STD-Cortesi-_x0028_unpub_x0029_" TYPE="STUDY">Cortesi (unpub)</LINK>; <LINK REF="STD-Grossman-2003" TYPE="STUDY">Grossman 2003</LINK>). One trial (<LINK REF="STD-Abol_x002d_Enein-1997" TYPE="STUDY">Abol-Enein 1997</LINK>) had only recorded overall disease-free survival and so could only be included in the analysis of this endpoint.</P>
<P>(2) Concurrent Chemoradiotherapy trials</P>
<P>Searches identified only one moderately sized eligible trial (<LINK REF="STD-Coppin-1996" TYPE="STUDY">Coppin 1996</LINK>) for this comparison. One hundred two patients were randomised and patient characteristics are similar to those for the neoadjuvant trials, most were male with a median age of 64 years (range 39 to 75 years), good performance status and with tumours that were predominantly T2 to T3. Cisplatin was given at 100 mg/m<SUP>2</SUP> per cycle in 3 cycles every 2 weeks. The median follow up for living patients was just over 13 years.</P>
<P>(3) Neoadjuvant plus adjuvant chemotherapy trials<BR/>One trial compared chemotherapy both before and after local treatment with local treatment alone (<LINK REF="STD-Shearer-1988" TYPE="STUDY">Shearer 1988</LINK>) and its results are presented alongside those of the neoadjuvant chemotherapy trials. The 398 patients in this trial were mostly male with a median age of 67 years (range 41 to 87 years) and all had T3 tumours. Methotrexate was given at 100 mg/m<SUP>2</SUP> per cycle for six cycles every 2 weeks. Patients in the chemotherapy arm also received a further 9 cycles of adjuvant methotrexate at 100 mg/m<SUP>2</SUP> per cycle every four weeks. The median follow up for living patients was slightly under 9 years. Data for 25 patients who had been excluded from the original analysis were unavailable.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All data were thoroughly checked for validity, consistency, plausibility and integrity of randomisation and follow-up. Any queries were resolved and the final database entries verified by the responsible investigator, data manager or statistician.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-06-09 09:04:47 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Survival</B>
<BR/>(1) Neoadjuvant chemotherapy trials<BR/>Survival data were supplied for 10 of the 11 trials with 2809 patients included. A total of 1691 deaths have been recorded. The confidence intervals for individual trial results are wide and the results of most individual trials are inconclusive. There is no clear evidence of statistical heterogeneity (P = 0.47) or inconsistency (I<SUP>2 </SUP>= 0%) between trials. The overall hazard ratio (HR) of 0.89 (95% CI 0.81 to 0.98) for these trials represents an 11% relative reduction in the risk of death associated with neoadjuvant chemotherapy which is conventionally significant (P = 0.022). This is equivalent to an absolute improvement of 4% at five years (95% CI 0% to 7%) increasing overall survival from 45% to 49%.</P>
<P>When we grouped the trials according to whether they used single agent platinum or platinum-based combination chemotherapy as pre-specified in the protocol (Outcome 1.01- Survival by chemotherapy type), we noted a difference in the effect of chemotherapy between the groups (interaction P = 0.029). The HR of 1.15 (95% CI 0.90 to 1.47) for those trials using single-agent chemotherapy is in favour of local treatment alone. This translates to an absolute benefit of -5% at 5 years (95% CI -14% to 4%). However, few trials and patients were included in this comparison, the confidence intervals are wide and the result is not conventionally significant (P = 0.264). By contrast, the combined HR for those trials using combination chemotherapy was 0.86 (95% CI 0.77 to 0.95, P = 0.003), equivalent to a 14% relative reduction in the risk of death; an absolute benefit of 5% at 5 years (95% CI 2% to 9%) improving survival from 45% to 50%. The survival curves for the combination chemotherapy trials, which separate by six months and remain apart thereafter, illustrate this benefit (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). [NB. Hazard Ratios calculated are labelled as Peto ORs in all of the forest plots.]</P>
<P>The other pre-specified subset grouping was by planned local treatment: cystectomy alone, radical radiotherapy alone or combined radiotherapy and cystectomy. Since we had noted evidence of a difference in the effect between the single agent and combination chemotherapy group, this analysis was restricted to trials that had used combination chemotherapy (Outcome 1.02 - Survival by local treatment). We noted no evidence of a difference in the effect of chemotherapy in the three local treatment groups (interaction P = 0.656).<BR/>
<B>
<BR/>Other Endpoints</B>
<BR/>Data on overall disease-free survival were available from 10 trials that included 2846 patients and 1847 events, of which 1606 (87%) were recurrences and 241 (13%) were deaths Further information is given in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. As for overall survival, in the pre-specified analysis according to whether trials had used single agent platinum or platinum-based combination chemotherapy, we noted a difference in the effect of chemotherapy between the group (interaction P=0.024) (Outcome 1.03 - Overall disease-free survival by chemotherapy type). For the combination chemotherapy trials, the combined HR of 0.78 (95% CI 0.71 to 03.86, P = 0.0000005) is equivalent to a 22% relative reduction in the risk of locoregional recurrence, metastases or death; an absolute disease-free survival benefit of 9% at 5 years (95% CI 5% to 12%).</P>
<P>For loco-regional disease-free survival and metastases-free survival, data were available for 7 trials that included 2180 patients with 1398 events (loco-regional disease-free survival) and 1345 events (metastases-free survival). For both endpoints approximately half of the events were deaths. Further information is given in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. Again, the results for these endpoints show a similar pattern to survival, both in terms of chemotherapy type (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>) and local treatment (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>) with a significant benefit of platinum-based combination chemotherapy.</P>
<P>There was insufficient data available to formally investigate toxicity or quality of life in these trials. However, where it was reported in the publications, the most common chemotherapy-related toxicities included nausea and vomiting haematological toxicities and impaired renal function.</P>
<P>
<B>Subsidiary Analyses of Survival in Patient Subgroups</B>
<BR/>Subgroup analyses across all trials would not have been appropriate because of the differences in effect noted for single agent and combination chemotherapy. We therefore restricted these analyses to those trials that had used combination chemotherapy and had been able to provide adequate baseline data (age, sex and T category available for all trials; performance status available for six trials; N category available in full for five trials and grade available in full for four trials; tumour diameter and renal function only available for one trial). The power of these analyses was inevitably limited. However we recorded no strong evidence to suggest that combination chemotherapy was differentially effective in groups of patients defined by age, sex, t category, n category, grade, performance status or renal function. There was some suggestion of a differential effect between groups of patients defined by tumour diameter (trend P = 0.008), however this analysis was based on data that was largely from one trial (<LINK REF="STD-MRC_x002f_EORTC-1999" TYPE="STUDY">MRC/EORTC 1999</LINK>) and should therefore be interpreted with caution (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
<P>(2) Concurrent Chemoradiotherapy Trials<BR/>The HR of 0.76 (95% CI 0.49 to 1.18) suggests a 24% reduction in the relative risk of death associated with concurrent chemoradiotherapy, although this was not conventionally significant (P = 0.229) (Outcome 2.01 - Survival).</P>
<P>(3) Neoadjuvant plus Adjuvant Chemotherapy Trials<BR/>The HR of 0.85 (95% CI 0.68 to 1.05) represents a 15% relative reduction in the risk of death with neoadjuvant and adjuvant chemotherapy, compared with control, but this was not conventionally significant (P = 0.136) (Outcome 3.01 - Survival).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-29 12:20:37 -0500" MODIFIED_BY="[Empty name]">
<P>Our findings show a beneficial effect of neoadjuvant chemotherapy. This effect was most clear in those trials that used combination, platinum-based chemotherapy, with a 5% improvement in survival at five years. The results for disease-free survival, locoregional disease-free survival and metastases-free survival lend support to the evidence of survival benefits associated with combination chemotherapy. We had insufficient evidence to formally test whether any of the specific combinations of chemotherapy used in these trials is more or less active, however there is no evidence of statistical heterogeneity between the trials in the combination chemotherapy group. The effect of combination chemotherapy also appears independent of the local treatment used, with a similar benefit of chemotherapy seen whether cystectomy, radiotherapy or radiotherapy and cystectomy was used as local treatment. This analysis however cannot directly measure the underlying relative efficacy of the various local treatments.</P>
<P>The subgroup analyses are exploratory in nature and had fairly low power, these analyses should therefore be interpreted with caution. No strong evidence was seen that the effect of neoadjuvant combination chemotherapy varied across patient subgroups. However we found a suggestion of a trend in the effect of chemotherapy when patients were grouped according to tumour diameter. Although tumour diameter is difficult to measure accurately, this observation might warrant further investigation. The overall absolute benefit of 5% at 5 years therefore provides the best estimate of effect in all subgroups however the clinical interpretation of this benefit may vary due to the differing underlying prognoses of these patients. For example, at 5 years, neoadjuvant chemotherapy improves survival from 55% to 60% in patients with T1to T2 disease, from 40% to 45% in T3 and from 25% to 30% in the group of patients with T4 disease.</P>
<P>Despite a significant difference in the effect of neoadjuvant chemotherapy between groups of trials using single agent chemotherapy and combination chemotherapy, we did not find sufficient evidence to reliably determine the effect of single agent cisplatin chemotherapy on survival. Indeed, only three small trials including a total of 376 patients used single-agent cisplatin and the combined HR of survival for this group is based on just 261 events. With such low power, the results are far less reliable than those for the combination chemotherapy group. Furthermore, these three trials are among the earliest trials of neoadjuvant chemotherapy and may be less relevant in today's context, where combination regimens are preferred.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Our findings show a clear survival benefit associated with neoadjuvant combination chemotherapy for patients with invasive bladder cancer. However, few of the trials in this meta-analysis measured toxicity or quality of life in ways that would allow data to be combined in a meta-analysis and clearly these are major issues for patients and clinicians when considering their treatment options. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>In light of these results, promising new drug regimens or treatment approaches should be compared in randomised trials against neoadjuvant platinum-based combination chemotherapy. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are grateful to the British Medical Research Council for funding this work. We would like to thank all those patients who took part in these trials and contributed to this research. The meta-analysis would not have been possible without the collaborating institutions that kindly supplied their trial data or without the help of those responsible for maintaining, updating and preparing trial data, in particular Jim Faulkner, Gareth Griffiths, David Lawrence, Rosario Madero, Jonas Nilsson, Giovanni Pappagallo, Ann-Marie Sargeant, Nory Teriana and Barbara Uscinska. We would also like to thank Cora Sternberg for comments and assistance throughout the project and Sarah Burdett for helpful comments on the report.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-05-29 12:21:15 -0500" MODIFIED_BY="[Empty name]">
<P>None given.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>All aspects of the meta-analysis were carried out under the auspices of the ABC group. <BR/>H Abol-Enein, P Bassi, M Boyer, C M L Coppin, E Cortesi, H.B Grossman, R R Hall, A Horwich, P-U Malmström, J A Martinez-Piñeiro, L Sengeløv, A Sherif and D M A Wallace collated and supplied the individual patients' data, contributed to the discussions of the results and commented on the drafts of the report. A V Bono, P J Goebell, S Groshen, F M Torti M Stöckle and U Studer contributed to the discussions of the results and commented on the drafts of the report. The project was organised by the Advisory Group, N W Clarke, D Raghavan, J T Roberts and R Sylvester and the Secretariat, M K B Parmar, L A Stewart, J F Tierney and C L Vale, who were responsible for formulating the questions, developing the protocol and discussing the preliminary results. The secretariat, MKB Parmar, L A Stewart, J F Tierney and C L Vale, were responsible for receiving, checking and analysing data. C L Vale managed the project and drafted the report, with detailed input from J F Tierney, L A Stewart and M K B Parmar.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-01-15 04:59:22 -0600" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-01-15 04:53:42 -0600" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-01-15 04:53:42 -0600" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Abol_x002d_Enein-1997" MODIFIED="2008-05-29 10:18:31 -0500" MODIFIED_BY="[Empty name]" NAME="Abol-Enein 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abol-Enein H, El-Mekresh M, El-Baz M, Ghoneim MA</AU>
<TI>Neo-adjuvant chemotherapy in the treatment of invasive transitional bladder cancer</TI>
<SO>British Journal of Urology</SO>
<YR>1997</YR>
<VL>79 (suppl 4)</VL>
<PG>174</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bassi-1999" MODIFIED="2008-05-29 10:18:38 -0500" MODIFIED_BY="[Empty name]" NAME="Bassi 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bassi P, Pappagallo GL, Sperandio P, et al</AU>
<TI>Neoadjuvant MVAC chemotherapy of invasive bladder cancer: results of a multicentre phase III trial</TI>
<SO>Journal of Urology</SO>
<YR>1999</YR>
<VL>161</VL>
<PG>264a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Coppin-1996" MODIFIED="2008-05-29 10:18:45 -0500" MODIFIED_BY="[Empty name]" NAME="Coppin 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coppin CML, Gospadorowicz MK, James K, et al</AU>
<TI>Improved local control of invasive bladder cancer by concurrent cisplatin and pre-operative or definitive radiation</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>2901-2907</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Cortesi-_x0028_unpub_x0029_" MODIFIED="2009-01-15 04:53:42 -0600" MODIFIED_BY="[Empty name]" NAME="Cortesi (unpub)" YEAR="">
<REFERENCE MODIFIED="2009-01-15 04:53:42 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Cortesi E</AU>
<TI>Italian Randomised Trial of Neoadjuvant MVEC in Locally Advanced Bladder Cancer</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Grossman-2003" MODIFIED="2009-01-15 04:35:35 -0600" MODIFIED_BY="[Empty name]" NAME="Grossman 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Raghavan D, Crawford ED</AU>
<TI>Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer</TI>
<SO>N Engl J Med</SO>
<YR>2003</YR>
<VL>349</VL>
<PG>859-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Malmstrom-1996" MODIFIED="2008-05-29 10:23:45 -0500" MODIFIED_BY="[Empty name]" NAME="Malmstrom 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malmstrom P-U, Rintala E, Walqvist R, et al</AU>
<TI>Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1</TI>
<SO>Journal of Urology</SO>
<YR>1996</YR>
<VL>155</VL>
<PG>1903-06</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Martinez-1995" MODIFIED="2008-05-29 10:23:53 -0500" MODIFIED_BY="[Empty name]" NAME="Martinez 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Pineiro JA, Gonzalez M, Arocena F et al</AU>
<TI>Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomised phase III study</TI>
<SO>Journal of Urology</SO>
<YR>1995</YR>
<VL>153</VL>
<PG>964-973</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MRC_x002f_EORTC-1999" MODIFIED="2008-05-29 10:24:00 -0500" MODIFIED_BY="[Empty name]" NAME="MRC/EORTC 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-urinary Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico (CUETO) Group</AU>
<TI>Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>533-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Natale-2001" MODIFIED="2009-01-15 04:38:02 -0600" MODIFIED_BY="[Empty name]" NAME="Natale 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Natale RB, Grossman HB, Blumenstein B, et al</AU>
<TI>SWOG 8710 (INT-0800). Randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer</TI>
<SO>Proceedings of the American Society for Clinical Oncology</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Raghavan-1991" MODIFIED="2008-05-29 10:24:13 -0500" MODIFIED_BY="[Empty name]" NAME="Raghavan 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallace DMA, Raghavan D, Kelly KA et al</AU>
<TI>Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder</TI>
<SO>British Journal of Urology</SO>
<YR>1991</YR>
<VL>67</VL>
<PG>608-615</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sengelov-2002" MODIFIED="2008-05-29 10:24:21 -0500" MODIFIED_BY="[Empty name]" NAME="Sengelov 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sengelov L, von der Maase H, Lundbech F, et al</AU>
<TI>Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumors</TI>
<SO>Acta Oncologia</SO>
<YR>2002</YR>
<VL>41</VL>
<PG>447-456</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Shearer-1988" MODIFIED="2008-05-29 10:24:29 -0500" MODIFIED_BY="[Empty name]" NAME="Shearer 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shearer RJ, Chilvers CED, Bloom HJG, Bliss JM, Horwich A, Babiker A</AU>
<TI>Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report</TI>
<SO>British Journal of Urology</SO>
<YR>1988</YR>
<VL>62</VL>
<PG>558-564</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sherif-2002" MODIFIED="2008-05-29 10:24:35 -0500" MODIFIED_BY="[Empty name]" NAME="Sherif 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherif A, Rintala E, Mestad O, et al</AU>
<TI>Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer. Nordic Cystectomy Trial 2</TI>
<SO>Scandinavian Journal of Urology and Nephrology</SO>
<YR>2002</YR>
<VL>6</VL>
<PG>419-425</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wallace-1991" MODIFIED="2008-05-29 10:24:43 -0500" MODIFIED_BY="[Empty name]" NAME="Wallace 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallace DMA, Raghavan D, Kelly KA et al</AU>
<TI>Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder</TI>
<SO>British Journal of Urology</SO>
<YR>1991</YR>
<VL>67</VL>
<PG>608-615</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-05-29 10:24:57 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Millikan-2001" MODIFIED="2008-05-29 10:24:51 -0500" MODIFIED_BY="[Empty name]" NAME="Millikan 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millikan R, Dinney C, Swanson D, et al</AU>
<TI>Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>4005-4013</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozono-1991" MODIFIED="2008-05-29 10:24:57 -0500" MODIFIED_BY="[Empty name]" NAME="Ozono 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozono S, kawata Y, Fukui Y, et al</AU>
<TI>Neoadjuvant therapy for locally invasive bladder cancer: results of a randomized trial in 40 patients</TI>
<SO>Urology International</SO>
<YR>1991</YR>
<VL>47</VL>
<NO>Suppl 1</NO>
<PG>116-119</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shipley-1998" MODIFIED="2008-05-29 10:17:27 -0500" MODIFIED_BY="[Empty name]" NAME="Shipley 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-05-29 10:17:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shipley W, Winter DA, Kaufman DS, et al</AU>
<TI>Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>3576-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-01-15 04:59:22 -0600" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-01-15 04:52:42 -0600" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ABCOC-1995" MODIFIED="2008-05-29 10:25:08 -0500" MODIFIED_BY="[Empty name]" NAME="ABCOC 1995" TYPE="JOURNAL_ARTICLE">
<AU>Advanced Bladder Cancer Overview Collaboration</AU>
<TI>Does neo-adjuvant cisplatin based chemotherapy improve survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomised clinical trials</TI>
<SO>British Journal of Urology</SO>
<YR>1995</YR>
<VL>75</VL>
<PG>206-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AOCTG-1991" MODIFIED="2008-05-29 10:25:15 -0500" MODIFIED_BY="[Empty name]" NAME="AOCTG 1991" TYPE="JOURNAL_ARTICLE">
<AU>Advanced Ovarian Cancer Trialists Group</AU>
<TI>Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials</TI>
<SO>Br Med J</SO>
<YR>1991</YR>
<VL>303</VL>
<PG>884-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1998" MODIFIED="2008-05-29 10:25:22 -0500" MODIFIED_BY="[Empty name]" NAME="Clarke 1998" TYPE="JOURNAL_ARTICLE">
<AU>Clarke M, Godwin J</AU>
<TI>Systematic reviews using individual patient data: A map for the minefields?</TI>
<SO>Annals of Oncology</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>827-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2008-05-29 10:25:28 -0500" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>British Medical Journal</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fagg-1984" MODIFIED="2008-05-29 10:25:37 -0500" MODIFIED_BY="[Empty name]" NAME="Fagg 1984" TYPE="JOURNAL_ARTICLE">
<AU>Fagg SL, Dawson-Edwards P, Hughes MA, Lateif T, Rolfe EB, Fielding JW</AU>
<TI>Cis-diamminedichloroplatinum (DPP) as initial treatment of invasive bladder cancer</TI>
<SO>British Journal of Urology</SO>
<YR>1984</YR>
<VL>56</VL>
<PG>296-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1958" MODIFIED="2008-05-29 10:25:43 -0500" MODIFIED_BY="[Empty name]" NAME="Kaplan 1958" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan EL, Meier P</AU>
<TI>Nonparametric estimation from incomplete observation</TI>
<SO>Journal of the American Statistical Association</SO>
<YR>1958</YR>
<VL>53</VL>
<PG>457-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martinez-1998" MODIFIED="2008-05-29 10:25:49 -0500" MODIFIED_BY="[Empty name]" NAME="Martinez 1998" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Pineiro JA, Martinez-Pineiro L</AU>
<TI>The role of neoadjuvant chemotherapy for invasive bladder cancer</TI>
<SO>British Journal of Urology</SO>
<YR>1998</YR>
<VL>82</VL>
<PG>33-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parkin-1999" MODIFIED="2008-05-29 12:23:06 -0500" MODIFIED_BY="[Empty name]" NAME="Parkin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Parkin DM, Pisani P, Ferlay J</AU>
<TI>Global Cancer Statistics</TI>
<SO>CA Cancer J Clin</SO>
<YR>1999</YR>
<VL>49</VL>
<PG>33-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1995" MODIFIED="2008-05-29 10:26:03 -0500" MODIFIED_BY="[Empty name]" NAME="Parmar 1995" TYPE="BOOK">
<AU>Parmar MKB, Machin D</AU>
<SO>Survival analysis: a practical approach</SO>
<YR>1995</YR>
<PB>John Wiley &amp; Sons Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1999" MODIFIED="2008-05-29 12:22:56 -0500" MODIFIED_BY="[Empty name]" NAME="Parmar 1999" TYPE="BOOK_SECTION">
<AU>Parmar MKB and Burdett S</AU>
<TI>Neoadjuvant and Adjuvant chemotherapy</TI>
<SO>Clinical management of Bladder Cancer</SO>
<YR>1999</YR>
<PG>249-63</PG>
<EN>1st</EN>
<ED>Hall RR</ED>
<PB>Arnold</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raghavan-1984" MODIFIED="2009-01-15 04:43:47 -0600" MODIFIED_BY="[Empty name]" NAME="Raghavan 1984" TYPE="JOURNAL_ARTICLE">
<AU>Raghavan D, Pearson B, Coorey G, et al</AU>
<TI>Intravenous cis-platinum for invasive clinically non-metastatic bladder cancer: safety and feasibility of a new approach</TI>
<SO>Med J Aust</SO>
<YR>1984</YR>
<VL>140</VL>
<PG>276-278</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soloway-1981" MODIFIED="2008-05-29 10:26:52 -0500" MODIFIED_BY="[Empty name]" NAME="Soloway 1981" TYPE="JOURNAL_ARTICLE">
<AU>Soloway MS, Ikard M, Ford, K.</AU>
<TI>Cis-diamminedichloro-platinum (II) in locally advanced and metastatic urothelial cancer</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>47</VL>
<PG>476-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sternberg-2001" MODIFIED="2008-05-29 10:18:14 -0500" MODIFIED_BY="[Empty name]" NAME="Sternberg 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sternberg CN, Parmar MKB</AU>
<TI>Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>21s-26s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart-1993" MODIFIED="2008-05-29 10:27:01 -0500" MODIFIED_BY="[Empty name]" NAME="Stewart 1993" TYPE="JOURNAL_ARTICLE">
<AU>Stewart LA, Parmar MKB</AU>
<TI>Meta-analysis of the literature or of individual patient data: is there a difference?</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>418-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart-1995" MODIFIED="2008-05-29 10:27:10 -0500" MODIFIED_BY="[Empty name]" NAME="Stewart 1995" TYPE="JOURNAL_ARTICLE">
<AU>Stewart LA, Clarke MJ, on behalf of the Cochrane Working Party Group</AU>
<TI>Practical methodology of meta-analyses (overviews) using updated individual patient data</TI>
<SO>Stat Med</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>2057-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1985" MODIFIED="2008-05-29 10:27:17 -0500" MODIFIED_BY="[Empty name]" NAME="Yusuf 1985" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Peto R, Lewis J, Collins R, Sleight P</AU>
<TI>Beta-blockade during and after myocardial infarction: An overview of the randomised trials</TI>
<SO>Progress in Cardiovascular Diseases</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>5</NO>
<PG>335-71</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-01-15 04:59:22 -0600" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ABC-2003" NAME="ABC 2003" TYPE="JOURNAL_ARTICLE">
<AU>Advanced Bladder Cancer Meta-analysis Collaboration</AU>
<TI>Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<PG>1927-1934</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ABC-2005" MODIFIED="2009-01-15 04:49:15 -0600" MODIFIED_BY="[Empty name]" NAME="ABC 2005" TYPE="JOURNAL_ARTICLE">
<AU>Advanced Bladder Cancer Meta-analysis Collaboration</AU>
<TI>Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data</TI>
<SO>European Urology</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>2</NO>
<PG>202-206</PG>
<IDENTIFIERS MODIFIED="2009-01-15 04:48:38 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-ABCOC-2004" MODIFIED="2009-01-15 04:59:22 -0600" MODIFIED_BY="[Empty name]" NAME="ABCOC 2004" TYPE="COCHRANE_REVIEW">
<AU>Advanced Bladder Cancer Overview Collaboration</AU>
<TI>Neoadjuvant cisplatin for advanced bladder cancer (Cochrane review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2009-01-15 04:59:22 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-15 04:59:22 -0600" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001426 "/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-01-15 04:39:18 -0600" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-01-15 04:39:18 -0600" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Abol_x002d_Enein-1997">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1984-1996</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>196<BR/>T2-T4a, Nx, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery alone vs. neoadjuvant chemotherapy + surgery</P>
<P>Neoadjuvant CT:<BR/>2 cycles every 4 weeks of Carboplatin (300mg/m2), Methotrexate (50mg/m2) and Vinblastine (4mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Disease free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No data on overall survival</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bassi-1999">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1989-01996</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>206<BR/>T2-T4, N0, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery alone vs. neoadjuvant chemotherapy + surgery</P>
<P>Neoadjuvant CT:<BR/>4 cycles every 4 weeks of Cisplatin (70mg/m2), Methotrexate (30mg/m2), Vinblastine (3mg/m2) and Doxorubicin (30mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival<BR/>Disease-free survival <BR/>Locoregional disease-free survival <BR/>Metastases-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-29 10:15:12 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coppin-1996">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1985-1989</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>102<BR/>T2-T4b</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy or radiotherapy + surgery vs. concurrent chemoradiotherapy or concurrent chemoradiotherapy + surgery</P>
<P>CT:<BR/>3 cycles every 2 weeks of Cisplatin (100mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival <BR/>Disease-free survival <BR/>Locoregional disease-free survival<BR/>Metastases-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-29 10:15:12 -0500" MODIFIED_BY="[Empty name]">
<P>Concurrent chemotherapy and radiotherapy used therefore not included in main comparison of neoadjuvant chemotherapy +/- local treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cortesi-_x0028_unpub_x0029_">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1988-1992</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>171 (18 missing)<BR/>T2-T4, N0, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery alone vs. neoadjuvant chemotherapy + surgery</P>
<P>Neoadjuvant CT:<BR/>3 cycles every 4 weeks of Cisplatin (70mg/m2), Methotrexate (30mg/m2), Vinblastine (3mg/m2) and Epirubicin (40mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival <BR/>Disease-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Grossman-2003">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1987-1998</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>317<BR/>T2-T4a, N0, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery alone vs. neoadjuvant chemotherapy + surgery</P>
<P>Neoadjuvant CT:<BR/>3 cycles every 4 weeks of Cisplatin (70mg/m2), Methotrexate (30mg/m2), Vinblastine (3mg/m2) and Doxorubicin (30mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival <BR/>Overall disease free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not included in original analyses published in the Lancet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Malmstrom-1996">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1985-1989</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>325 (14 missing)<BR/>T1 (grade 3) - T4a, Nx, M0<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy + surgery vs. neoadjuvant chemotherapy + radiotherapy + surgery</P>
<P>Neoadjuvant CT:<BR/>2 cycles every 3 weeks of Cisplatin (70mg/m2) and Doxorubicin (30mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival<BR/>Disease-free survival<BR/>Locoregional disease-free survival<BR/>Metastases free-survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Martinez-1995">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1984-1989</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>122 (1 missing)<BR/>T2-T4a, Nx-N2, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery alone vs. neoadjuvant chemotherapy + surgery </P>
<P>Neoadjuvant CT:<BR/>3 cycles every 3 weeks of Cisplatin (100mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival <BR/>Disease free survival<BR/>Locoregional disease-free survival<BR/>Metastases free-survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Single agent cisplatin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-MRC_x002f_EORTC-1999">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1989-1995</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>976<BR/>T2 (grade 3), T3, T4a, N0, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cystectomy (+/- radiotherapy) or radiotherapy alone vs. Neoadjuvant chemotherapy plus cystectomy (+/- radiotherapy) or radiotherapy alone</P>
<P>Neoadjuvant CT:<BR/>3 cycles every 3 weeks of Cisplatin (100mg/m2), Methotrexate (30mg/m2) and Vinblastine (4mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival <BR/>Overall disease-free survival<BR/>Locoregional disease-free survival<BR/>Metastases-free survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-15 04:39:18 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Natale-2001">
<CHAR_METHODS MODIFIED="2009-01-15 04:35:52 -0600" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-15 04:38:22 -0600" MODIFIED_BY="[Empty name]">
<P>317</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-15 04:38:44 -0600" MODIFIED_BY="[Empty name]">
<P>Surgery alone vs. neoadjuvant chemotherapy + surgery</P>
<P>Neoadjuvant CT:<BR/>3 cycles every 4 weeks of Cisplatin (70mg/m2), Methotrexate (30mg/m2), Vinblastine (3mg/m2) and Doxorubicin (30mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-15 04:38:48 -0600" MODIFIED_BY="[Empty name]">
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-15 04:39:18 -0600" MODIFIED_BY="[Empty name]">
<P>Preliminary results of Grossman 2003 (presented at ASCO 2001)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Raghavan-1991">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1985-1988</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>96<BR/>T2-T4, Nx, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy alone vs. neoadjuvant chemotherapy + radiotherapy</P>
<P>Neoadjuvant CT:<BR/>2 cycles every 3 weeks of Cisplatin (100mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival<BR/>Disease free survival<BR/>Locoregional disease-free survival<BR/>Metastases free-survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Single agent cisplatin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sengelov-2002">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1989-1995</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>153<BR/>T2-T4b, Nx-N0, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery alone or radiotherapy alone vs. neoadjuvant chemotherapy + surgery or radiotherapy</P>
<P>Neoadjuvant CT:<BR/>3 cycles every 3 weeks of Cisplatin (100mg/m2) and Methotrexate (250mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival<BR/>Disease free survival<BR/>Locoregional disease-free survival <BR/>Metastases free-survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shearer-1988">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1978-1986</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>423 (25 missing)<BR/>T3-T4a, Nx, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy alone or radiotherapy + surgery vs. Neoadjuvant chemotherapy + radiotherapy or radiotherapy and surgery + adjuvant chemotherapy</P>
<P>Neoadjuvant CT: <BR/>6 cycles every 2 weeks of Methotrexate (100mg/m2) and Leucovorin (15mg) <BR/>Adjuvant CT:<BR/>9 cycles every 4 weeks of Methotrexate (100mg/m2) a</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival<BR/>Disease free survival<BR/>Locoregional disease-free survival <BR/>Metastases free-survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Trial used neoadjuvant and adjuvant chemotherapy therefore not included in the main comparison of neoadjuvant chemotherapy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sherif-2002">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1990-1997</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>317 (8 missing)<BR/>T2-T4a, Nx, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Surgery alone vs. Neoadjuvant chemotherapy + surgery </P>
<P>Neoadjuvant CT:<BR/>3 cycles every 3 weeks of Cisplatin (100mg/m2) and Methotrexate (250mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival<BR/>Disease free survival<BR/>Locoregional disease-free survival <BR/>Metastases free-survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wallace-1991">
<CHAR_METHODS>
<P>RCT<BR/>Accrual 1984-1988</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>159<BR/>T2-T4, Nx, M0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Radiotherapy alone vs. Neoadjuvant chemotherapy + radiotherapy</P>
<P>Neoadjuvant CT:<BR/>3 cycles every3 weeks of Cisplatin (100mg/m2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Single-agent cisplatin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Millikan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial compared neoadjuvant chemotherapy + local treatment on one arm with local treatment + adjuvant chemotherapy on the other</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ozono-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded by use of different treatments on both arms of the trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shipley-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Local treatment used was chemoradiotherapy and not surgery, radiotherapy or radiotherapy + surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-01-15 04:35:26 -0600" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-01-15 04:35:26 -0600" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Abol_x002d_Enein-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bassi-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Coppin-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cortesi-_x0028_unpub_x0029_">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Grossman-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-MRC_x002f_EORTC-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Malmstrom-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Martinez-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Natale-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Raghavan-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sengelov-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Shearer-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sherif-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wallace-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-01-15 04:21:41 -0600" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-01-15 04:11:16 -0600" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Characteristics of included patients</TITLE>
<TABLE COLS="5" ROWS="35">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P>Neo CT (n=1502)</P>
</TH>
<TH>
<P>Control (n=1503)</P>
</TH>
<TH>
<P>Total (n=3005)</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Age<BR/>
</P>
</TD>
<TD>
<P>&lt;55<BR/>
</P>
</TD>
<TD>
<P>265 (18%)<BR/>
</P>
</TD>
<TD>
<P>287 (19%)<BR/>
</P>
</TD>
<TD>
<P>552</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>55-64</P>
</TD>
<TD>
<P>599 (40%)</P>
</TD>
<TD>
<P>532 (35%)</P>
</TD>
<TD>
<P>1131</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>&#8805;65</P>
</TD>
<TD>
<P>638 (42%)</P>
</TD>
<TD>
<P>684 (46%)</P>
</TD>
<TD>
<P>1322</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Sex</P>
</TD>
<TD>
<P>Male</P>
</TD>
<TD>
<P>1267 (84%)</P>
</TD>
<TD>
<P>1273 (85%)</P>
</TD>
<TD>
<P>2540</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Female</P>
</TD>
<TD>
<P>235 (16%)</P>
</TD>
<TD>
<P>230 (15%)</P>
</TD>
<TD>
<P>465</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>T category</P>
</TD>
<TD>
<P>T0-1</P>
</TD>
<TD>
<P>33 (2%)</P>
</TD>
<TD>
<P>31 (2%)</P>
</TD>
<TD>
<P>64</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>T2</P>
</TD>
<TD>
<P>507 (34%)</P>
</TD>
<TD>
<P>541 (36%)</P>
</TD>
<TD>
<P>1048</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>T3-T4a</P>
</TD>
<TD>
<P>927 (62%)</P>
</TD>
<TD>
<P>898 (60%)</P>
</TD>
<TD>
<P>1825</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>T4b</P>
</TD>
<TD>
<P>11 (1%)</P>
</TD>
<TD>
<P>9 (1%)</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>24 (2%)</P>
</TD>
<TD>
<P>24 (2%)</P>
</TD>
<TD>
<P>48</P>
</TD>
</TR>
<TR>
<TD>
<P>N category</P>
</TD>
<TD>
<P>N0</P>
</TD>
<TD>
<P>797 (53%)</P>
</TD>
<TD>
<P>765 (51%)</P>
</TD>
<TD>
<P>1562</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>N1/N2</P>
</TD>
<TD>
<P>55 (4%)</P>
</TD>
<TD>
<P>62 (4%)</P>
</TD>
<TD>
<P>117</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Nx/Unknown</P>
</TD>
<TD>
<P>650 (43%)</P>
</TD>
<TD>
<P>676 (45%)</P>
</TD>
<TD>
<P>1326</P>
</TD>
</TR>
<TR>
<TD>
<P>Grade</P>
</TD>
<TD>
<P>G0-1</P>
</TD>
<TD>
<P>155 (10%)</P>
</TD>
<TD>
<P>136 (9%)</P>
</TD>
<TD>
<P>291</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>G2</P>
</TD>
<TD>
<P>179 (12%)</P>
</TD>
<TD>
<P>219 (15%)</P>
</TD>
<TD>
<P>398</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>G3</P>
</TD>
<TD>
<P>805 (54%)</P>
</TD>
<TD>
<P>789 (52%)</P>
</TD>
<TD>
<P>1594</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>G4</P>
</TD>
<TD>
<P>10 (1%)</P>
</TD>
<TD>
<P>28 (2%)</P>
</TD>
<TD>
<P>38</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>353 (24%)</P>
</TD>
<TD>
<P>331(22%)</P>
</TD>
<TD>
<P>684</P>
</TD>
</TR>
<TR>
<TD>
<P>Performance Status</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>774 (52%)</P>
</TD>
<TD>
<P>756 (50%)</P>
</TD>
<TD>
<P>1530</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>292 (19%)</P>
</TD>
<TD>
<P>312 (21%)</P>
</TD>
<TD>
<P>604</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>49 (3%)</P>
</TD>
<TD>
<P>60 (4%)</P>
</TD>
<TD>
<P>109</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>13 (1%)</P>
</TD>
<TD>
<P>8 (1%)</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>374 (25%)</P>
</TD>
<TD>
<P>367 (24%)</P>
</TD>
<TD>
<P>741</P>
</TD>
</TR>
<TR>
<TD>
<P>Tumour diameter (cm)</P>
</TD>
<TD>
<P>&lt;2.5</P>
</TD>
<TD>
<P>96 (6%)</P>
</TD>
<TD>
<P>101 (7%)</P>
</TD>
<TD>
<P>197</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>2.5-5.0</P>
</TD>
<TD>
<P>247 (16%)</P>
</TD>
<TD>
<P>284 (19%)</P>
</TD>
<TD>
<P>531</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>&gt;5.0</P>
</TD>
<TD>
<P>238 (16%)</P>
</TD>
<TD>
<P>205 (14%)</P>
</TD>
<TD>
<P>443</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>921 (61%)</P>
</TD>
<TD>
<P>913 (61%)</P>
</TD>
<TD>
<P>1834</P>
</TD>
</TR>
<TR>
<TD>
<P>Renal function (GFR)</P>
</TD>
<TD>
<P>&#8806;59</P>
</TD>
<TD>
<P>40 (3%)</P>
</TD>
<TD>
<P>42 (3%)</P>
</TD>
<TD>
<P>82</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>60-69</P>
</TD>
<TD>
<P>119 (8%)</P>
</TD>
<TD>
<P>134 (9%)</P>
</TD>
<TD>
<P>253</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>&gt;69</P>
</TD>
<TD>
<P>330 (22%)</P>
</TD>
<TD>
<P>305 (20%)</P>
</TD>
<TD>
<P>635</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>1013 (67%)</P>
</TD>
<TD>
<P>1022 (68%)</P>
</TD>
<TD>
<P>2035</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>First events reported by treatment arm</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TH>
<P>First event</P>
</TH>
<TH>
<P>Neo CT (n =1502)</P>
</TH>
<TH>
<P>Control (n = 1503)</P>
</TH>
</TR>
<TR>
<TD>
<P>Alive (no recurrence)</P>
</TD>
<TD>
<P>451 (30%)</P>
</TD>
<TD>
<P>388 (26%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Local recurrence</P>
</TD>
<TD>
<P>208 (14%)</P>
</TD>
<TD>
<P>213 (14%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Metastasis</P>
</TD>
<TD>
<P>150 (10%)</P>
</TD>
<TD>
<P>196 (13%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Local recurrence <BR/>and metastases together</P>
</TD>
<TD>
<P>176 (12%)</P>
</TD>
<TD>
<P>200 (13%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Death (No recurrence)</P>
</TD>
<TD>
<P>194 (13%)</P>
</TD>
<TD>
<P>306 (20%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Unknown</P>
</TD>
<TD>
<P>323 (22%)</P>
</TD>
<TD>
<P>200 (13%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-05-29 10:15:12 -0500" MODIFIED_BY="[Empty name]" NO="3">
<TITLE>Results for all endpoints by chemotherapy type</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TH>
<P>Endpoint</P>
</TH>
<TH>
<P>CT Type</P>
</TH>
<TH>
<P>No patients / events</P>
</TH>
<TH>
<P>HR (95% CI)</P>
</TH>
<TH>
<P>Effect P value</P>
</TH>
<TH>
<P>Abs benefit (95% CI)</P>
</TH>
<TH>
<P>Interaction p-value</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Overall survival</P>
</TD>
<TD>
<P>Single agent platinum</P>
</TD>
<TD>
<P>261/376</P>
</TD>
<TD>
<P>1.15 (0.90-1.47)</P>
</TD>
<TD>
<P>0.26</P>
</TD>
<TD>
<P>-5% (-14% to 4%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Platinum based combinations</P>
</TD>
<TD>
<P>1430/2433</P>
</TD>
<TD>
<P>0.86 (0.77-0.95)</P>
</TD>
<TD>
<P>0.003</P>
</TD>
<TD>
<P>5% (2% to 9%)</P>
</TD>
<TD>
<P>0.029</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All trials</P>
</TD>
<TD>
<P>1691/2890</P>
</TD>
<TD>
<P>0.89 (0.81-0.98)</P>
</TD>
<TD>
<P>0.022</P>
</TD>
<TD>
<P>4% (0% to 7%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Disease-free survival</P>
</TD>
<TD>
<P>Single agent platinum</P>
</TD>
<TD>
<P>166/217</P>
</TD>
<TD>
<P>1.14 (0.83-1.55)</P>
</TD>
<TD>
<P>0.42</P>
</TD>
<TD>
<P>-5% (-16% to 7%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Platinum based combinations</P>
</TD>
<TD>
<P>1681/2629</P>
</TD>
<TD>
<P>0.78 (0.71-0.86)</P>
</TD>
<TD>
<P>0.0000005</P>
</TD>
<TD>
<P>9% (5% to 12%)</P>
</TD>
<TD>
<P>0.024</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All trials</P>
</TD>
<TD>
<P>1847/2846</P>
</TD>
<TD>
<P>0.81 (0.74-0.89)</P>
</TD>
<TD>
<P>0.000005</P>
</TD>
<TD>
<P>8% (4% to 11%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Locoregional disease-free survival</P>
</TD>
<TD>
<P>Single agent platinum</P>
</TD>
<TD>
<P>166/217</P>
</TD>
<TD>
<P>1.12 (0.82-1.52)</P>
</TD>
<TD>
<P>0.49</P>
</TD>
<TD>
<P>-4% (-15% to 7%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Platinum based combinations</P>
</TD>
<TD>
<P>1232/1963</P>
</TD>
<TD>
<P>0.87 (0.77-0.97)</P>
</TD>
<TD>
<P>0.012</P>
</TD>
<TD>
<P>5% (3% to 11%)</P>
</TD>
<TD>
<P>0.131</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All trials</P>
</TD>
<TD>
<P>1398/2180</P>
</TD>
<TD>
<P>0.89 (0.80-0.99)</P>
</TD>
<TD>
<P>0.032</P>
</TD>
<TD>
<P>4% (0% to 8%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Metastases-free survival</P>
</TD>
<TD>
<P>Single agent platinum</P>
</TD>
<TD>
<P>154/217</P>
</TD>
<TD>
<P>1.21 (0.88-1.67)</P>
</TD>
<TD>
<P>0.25</P>
</TD>
<TD>
<P>-7% (-18% to 5%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Platinum based combinations</P>
</TD>
<TD>
<P>1181/1963</P>
</TD>
<TD>
<P>0.82 (0.73-0.92)</P>
</TD>
<TD>
<P>0.001</P>
</TD>
<TD>
<P>7% (3% to 11%)</P>
</TD>
<TD>
<P>0.025</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All trials</P>
</TD>
<TD>
<P>1335/2180</P>
</TD>
<TD>
<P>0.86 (0.77-0.95)</P>
</TD>
<TD>
<P>0.004</P>
</TD>
<TD>
<P>5% (2% to 9%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Results for all endpoints by local treatment (combination CT trials only)</TITLE>
<TABLE COLS="4" ROWS="13">
<TR>
<TH>
<P>Endpoint</P>
</TH>
<TH>
<P>Local treatment type</P>
</TH>
<TH>
<P>HR (95% CI)</P>
</TH>
<TH>
<P>Interaction p-value</P>
</TH>
</TR>
<TR>
<TD>
<P>Overall survival</P>
</TD>
<TD>
<P>Cystectomy</P>
</TD>
<TD>
<P>0.86 (0.75-0.98)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Radiotherapy</P>
</TD>
<TD>
<P>0.90 (0.74-1.11)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Radiotherapy + cystectomy</P>
</TD>
<TD>
<P>0.77 (0.58-1.02)</P>
</TD>
<TD>
<P>0.656</P>
</TD>
</TR>
<TR>
<TD>
<P>Disease-free survival</P>
</TD>
<TD>
<P>Cystectomy</P>
</TD>
<TD>
<P>0.75 (0.66-0.84)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Radiotherapy</P>
</TD>
<TD>
<P>0.92 (0.76-1.11)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Radiotherapy + cystectomy</P>
</TD>
<TD>
<P>0.71 (0.54-0.94)</P>
</TD>
<TD>
<P>0.158</P>
</TD>
</TR>
<TR>
<TD>
<P>Locoregional disease free survival</P>
</TD>
<TD>
<P>Cystectomy</P>
</TD>
<TD>
<P>0.86 (0.69-1.01)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Radiotherapy</P>
</TD>
<TD>
<P>0.96 (0.79-1.16)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Radiotherapy + cystectomy</P>
</TD>
<TD>
<P>0.73 (0.55-0.96)</P>
</TD>
<TD>
<P>0.286</P>
</TD>
</TR>
<TR>
<TD>
<P>Metastases free survival</P>
</TD>
<TD>
<P>Cystectomy</P>
</TD>
<TD>
<P>0.82 (0.70-0.96)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Radiotherapy</P>
</TD>
<TD>
<P>0.87 (0.71-1.06)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Radiotherapy + cystectomy</P>
</TD>
<TD>
<P>0.73 (0.56-0.97)</P>
</TD>
<TD>
<P>0.649</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2009-01-15 04:21:41 -0600" MODIFIED_BY="[Empty name]" NO="5">
<TITLE>Results of subgroup analyses (survival - combination CT trials only)</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TH>
<P>Subgroup</P>
</TH>
<TH>
<P>Categories</P>
</TH>
<TH>
<P>Interaction</P>
</TH>
<TH>
<P>Trend</P>
</TH>
</TR>
<TR>
<TD>
<P>Age</P>
</TD>
<TD>
<P>&#8826;55, 55 to &#8826; 65, &#8807; 65</P>
</TD>
<TD>
<P>1.572 (2 d.f.) P=0.456</P>
</TD>
<TD>
<P>0.482 (1 d.f.) P=0.488</P>
</TD>
</TR>
<TR>
<TD>
<P>Sex</P>
</TD>
<TD>
<P>Male, Female</P>
</TD>
<TD>
<P>0.266 (1d.f) P=0.606</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>T category</P>
</TD>
<TD>
<P>T1-2, T3, T4</P>
</TD>
<TD>
<P>0.324 (2 d.f.) P=0.850</P>
</TD>
<TD>
<P>0.108 (1 d.f.) P=0.742</P>
</TD>
</TR>
<TR>
<TD>
<P>N category</P>
</TD>
<TD>
<P>N0, N1/N2</P>
</TD>
<TD>
<P>0.080 (1d.f.) P=0.777</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Grade</P>
</TD>
<TD>
<P>G1/G2, G3/G4</P>
</TD>
<TD>
<P>1.154 (1d.f.) P=0.283</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Tumour diameter (cm)</P>
</TD>
<TD>
<P>&#8826; 2.5, 2.5 to 5.0, &#8827; 5.0</P>
</TD>
<TD>
<P>7.733 (2 d.f.) P=0.021</P>
</TD>
<TD>
<P>7.079 (1d.f.) P=0.008</P>
</TD>
</TR>
<TR>
<TD>
<P>Performance status</P>
</TD>
<TD>
<P>0, 1, 2 to 3</P>
</TD>
<TD>
<P>1.511 (2 d.f.) P=0.470</P>
</TD>
<TD>
<P>0.004 (1 d.f.) P=0.95</P>
</TD>
</TR>
<TR>
<TD>
<P>Renal function (GFR)</P>
</TD>
<TD>
<P>&#8806; 59, 60 to 69, &#8827; 69</P>
</TD>
<TD>
<P>3.573 (2 d.f.) P=0.168</P>
</TD>
<TD>
<P>3.564 (1d.f.) P=0.059</P>
</TD>
</TR>
<TR>
<TD>
<P>d.f. = degrees of freedom</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Neoadjuvant CT + Local treatment vs Local treatment alone</NAME>
<IPD_OUTCOME CHI2="8.669138925761104" CI_END="0.9843686275441711" CI_START="0.8128970477469336" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.8945335942407963" ESTIMABLE="YES" EVENTS_1="822" EVENTS_2="869" I2="0.0" I2_Q="78.94958209126324" ID="CMP-001.01" LOG_CI_END="-0.006842235990735313" LOG_CI_START="-0.08996445370066326" LOG_EFFECT_SIZE="-0.048403344845699296" NO="1" P_CHI2="0.4683588801271945" P_Q="0.029289882769220066" P_Z="0.022451918757341423" Q="4.750499511864606" SCALE="10.0" SORT_BY="USER" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1406" TOTAL_2="1403" WEIGHT="99.99999999999999" Z="2.282634300251883">
<NAME>Survival by chemotherapy type</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.107345412137477" CI_END="1.4698952140667692" CI_START="0.8998139215652714" DF="2" EFFECT_SIZE="1.1500574667639194" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="125" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.1672863758538694" LOG_CI_START="-0.04584729188593822" LOG_EFFECT_SIZE="0.06071954198396559" NO="1" P_CHI2="0.5748348638262291" P_Z="0.2641028412158085" STUDIES="3" TAU2="0.0" TOTAL_1="186" TOTAL_2="190" WEIGHT="15.210031945835121" Z="1.1167462814145797">
<NAME>Single agent platinum</NAME>
<IPD_DATA CI_END="1.6108364814398093" CI_START="0.7594697698907245" EFFECT_SIZE="1.106065826201441" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="50" LOG_CI_END="0.2070514567366043" LOG_CI_START="-0.11948950821453587" LOG_EFFECT_SIZE="0.04378097426103418" ORDER="1" O_E="2.74" SE="0.19181177921614534" STUDY_ID="STD-Wallace-1991" TOTAL_1="83" TOTAL_2="76" VAR="27.18" WEIGHT="6.479759691031325"/>
<IPD_DATA CI_END="1.573764857312973" CI_START="0.6566190545886703" EFFECT_SIZE="1.016545125783267" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="38" LOG_CI_END="0.19693984314361238" LOG_CI_START="-0.18268651852620083" LOG_EFFECT_SIZE="0.0071266623087057855" ORDER="2" O_E="0.33" SE="0.22299440402564558" STUDY_ID="STD-Martinez-1995" TOTAL_1="62" TOTAL_2="59" VAR="20.11" WEIGHT="4.794259285748343"/>
<IPD_DATA CI_END="2.3087224930682955" CI_START="0.8798244140318761" EFFECT_SIZE="1.4252264432805142" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="37" LOG_CI_END="0.3633717341419337" LOG_CI_START="-0.05560399106088912" LOG_EFFECT_SIZE="0.15388387154052224" ORDER="3" O_E="5.85" SE="0.24610841494742633" STUDY_ID="STD-Raghavan-1991" TOTAL_1="41" TOTAL_2="55" VAR="16.51" WEIGHT="3.936012969055452"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.8112940017590207" CI_END="0.9487609850194713" CI_START="0.7707020555274536" DF="6" EFFECT_SIZE="0.8551093739158506" ESTIMABLE="YES" EVENTS_1="686" EVENTS_2="744" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.022843182684635643" LOG_CI_START="-0.11311348271239537" LOG_EFFECT_SIZE="-0.06797833269851554" NO="2" P_CHI2="0.8321314443355148" P_Z="0.003158108160208546" STUDIES="7" TAU2="0.0" TOTAL_1="1220" TOTAL_2="1213" WEIGHT="84.78996805416486" Z="2.9519140576069827">
<NAME>Platinum based combination chemotherapy</NAME>
<IPD_DATA CI_END="1.3501564800583572" CI_START="0.6447694189610014" EFFECT_SIZE="0.933027121338741" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="60" LOG_CI_END="0.13038410515249274" LOG_CI_START="-0.1905955690494953" LOG_EFFECT_SIZE="-0.030105731948501295" ORDER="1" O_E="-1.95" SE="0.18854504950126014" STUDY_ID="STD-Bassi-1999" TOTAL_1="102" TOTAL_2="104" VAR="28.13" WEIGHT="6.706241357936394"/>
<IPD_DATA CI_END="1.00761596323299" CI_START="0.5819838397467285" EFFECT_SIZE="0.7657781710602842" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="108" LOG_CI_END="0.0032950392241345" LOG_CI_START="-0.23508907446739946" LOG_EFFECT_SIZE="-0.11589701762163249" ORDER="2" O_E="-13.61" SE="0.14002800840280097" STUDY_ID="STD-Grossman-2003" TOTAL_1="158" TOTAL_2="159" VAR="51.0" WEIGHT="12.158489486482619"/>
<IPD_DATA CI_END="1.4043950208788294" CI_START="0.5950741901330667" EFFECT_SIZE="0.914176804385443" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="41" LOG_CI_END="0.14748928105486128" LOG_CI_START="-0.22542888577262332" LOG_EFFECT_SIZE="-0.03896980235888106" ORDER="3" O_E="-1.87" SE="0.21905397716916175" STUDY_ID="STD-Cortesi-_x0028_unpub_x0029_" TOTAL_1="82" TOTAL_2="71" VAR="20.84" WEIGHT="4.9682925666332896"/>
<IPD_DATA CI_END="0.9985922932316086" CI_START="0.7199938446158176" EFFECT_SIZE="0.8479270631413718" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="301" LOG_CI_END="-6.117899932074352E-4" LOG_CI_START="-0.1426712164309697" LOG_EFFECT_SIZE="-0.07164150321208852" ORDER="4" O_E="-23.69" SE="0.08344641029504356" STUDY_ID="STD-MRC_x002f_EORTC-1999" TOTAL_1="491" TOTAL_2="485" VAR="143.61" WEIGHT="34.23687598340724"/>
<IPD_DATA CI_END="1.0569803434329326" CI_START="0.5593483719016095" EFFECT_SIZE="0.7689084693454838" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="84" LOG_CI_END="0.024066910847645253" LOG_CI_START="-0.25231762168451516" LOG_EFFECT_SIZE="-0.11412535541843495" ORDER="5" O_E="-9.97" SE="0.16234964253489187" STUDY_ID="STD-Malmstrom-1996" TOTAL_1="151" TOTAL_2="160" VAR="37.94" WEIGHT="9.04496257092452"/>
<IPD_DATA CI_END="1.4958583902853273" CI_START="0.7477510349419598" EFFECT_SIZE="1.0576056256764463" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="60" LOG_CI_END="0.17489048174460153" LOG_CI_START="-0.1262429772009957" LOG_EFFECT_SIZE="0.024323752271802914" ORDER="6" O_E="1.79" SE="0.17688728441930626" STUDY_ID="STD-Sengelov-2002" TOTAL_1="78" TOTAL_2="75" VAR="31.96" WEIGHT="7.619320078195774"/>
<IPD_DATA CI_END="1.1627217367842848" CI_START="0.6358437241398122" EFFECT_SIZE="0.8598309829584126" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="90" LOG_CI_END="0.0654757915653571" LOG_CI_START="-0.19664961089791827" LOG_EFFECT_SIZE="-0.06558690966628057" ORDER="7" O_E="-6.37" SE="0.15397375894859666" STUDY_ID="STD-Sherif-2002" TOTAL_1="158" TOTAL_2="159" VAR="42.18" WEIGHT="10.055786010585036"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="3.316295845836579" CI_END="0.9491355801099526" CI_START="0.7704426046013322" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.8551341932467139" ESTIMABLE="YES" EVENTS_1="682" EVENTS_2="739" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.02267174596269234" LOG_CI_START="-0.11325970922768473" LOG_EFFECT_SIZE="-0.06796572759518853" NO="2" P_CHI2="0.950424887719313" P_Q="0.6565385765254386" P_Z="0.0032713638627099987" Q="0.8415477032678074" SCALE="10.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1214" TOTAL_2="1207" WEIGHT="100.0" Z="2.9410171830435354">
<NAME>Survival by local treatment type (combination CT trials only)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="2.286237259658421" CI_END="0.9779844970232577" CI_START="0.7476462927614915" DF="5" EFFECT_SIZE="0.8550944296261382" ESTIMABLE="YES" EVENTS_1="413" EVENTS_2="444" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.009668029579082065" LOG_CI_START="-0.12630381581589967" LOG_EFFECT_SIZE="-0.06798592269749085" NO="1" P_CHI2="0.8082862323077327" P_Z="0.022319289473796612" STUDIES="6" TAU2="0.0" TOTAL_1="762" TOTAL_2="746" WEIGHT="60.32222442449812" Z="2.2848898137018647">
<NAME>Cystectomy</NAME>
<IPD_DATA CI_END="1.3501564800583572" CI_START="0.6447694189610014" EFFECT_SIZE="0.933027121338741" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="60" LOG_CI_END="0.13038410515249274" LOG_CI_START="-0.1905955690494953" LOG_EFFECT_SIZE="-0.030105731948501295" ORDER="1" O_E="-1.95" SE="0.18854504950126014" STUDY_ID="STD-Bassi-1999" TOTAL_1="102" TOTAL_2="104" VAR="28.13" WEIGHT="7.9650026899227"/>
<IPD_DATA CI_END="1.00761596323299" CI_START="0.5819838397467285" EFFECT_SIZE="0.7657781710602842" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="108" LOG_CI_END="0.0032950392241345" LOG_CI_START="-0.23508907446739946" LOG_EFFECT_SIZE="-0.11589701762163249" ORDER="2" O_E="-13.61" SE="0.14002800840280097" STUDY_ID="STD-Grossman-2003" TOTAL_1="158" TOTAL_2="159" VAR="51.0" WEIGHT="14.440637653254807"/>
<IPD_DATA CI_END="1.4043950208788294" CI_START="0.5950741901330667" EFFECT_SIZE="0.914176804385443" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="41" LOG_CI_END="0.14748928105486128" LOG_CI_START="-0.22542888577262332" LOG_EFFECT_SIZE="-0.03896980235888106" ORDER="3" O_E="-1.87" SE="0.21905397716916175" STUDY_ID="STD-Cortesi-_x0028_unpub_x0029_" TOTAL_1="82" TOTAL_2="71" VAR="20.84" WEIGHT="5.900840954780984"/>
<IPD_DATA CI_END="1.0695708131267765" CI_START="0.6577372348991182" EFFECT_SIZE="0.8387470114133387" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="136" LOG_CI_END="0.0292095432152844" LOG_CI_START="-0.1819475717738742" LOG_EFFECT_SIZE="-0.0763690142792949" ORDER="4" O_E="-11.43" SE="0.12403473458920845" STUDY_ID="STD-MRC_x002f_EORTC-1999" TOTAL_1="245" TOTAL_2="238" VAR="65.0" WEIGHT="18.404734263952207"/>
<IPD_DATA CI_END="3.085686466391003" CI_START="0.6136049074094851" EFFECT_SIZE="1.3760059442111987" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.48935179572781395" LOG_CI_START="-0.21211117570128984" LOG_EFFECT_SIZE="0.13862031001326203" ORDER="5" O_E="1.88" SE="0.4120428217151646" STUDY_ID="STD-Sengelov-2002" TOTAL_1="17" TOTAL_2="15" VAR="5.89" WEIGHT="1.6677520740719767"/>
<IPD_DATA CI_END="1.1627217367842848" CI_START="0.6358437241398122" EFFECT_SIZE="0.8598309829584126" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="90" LOG_CI_END="0.0654757915653571" LOG_CI_START="-0.19664961089791827" LOG_EFFECT_SIZE="-0.06558690966628057" ORDER="6" O_E="-6.37" SE="0.15397375894859666" STUDY_ID="STD-Sherif-2002" TOTAL_1="158" TOTAL_2="159" VAR="42.18" WEIGHT="11.943256788515447"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="0.18824332516753176" CI_END="1.1090092987351383" CI_START="0.7373744039129052" DF="1" EFFECT_SIZE="0.9042981093581317" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="189" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.044935187603108495" LOG_CI_START="-0.13231194190255946" LOG_EFFECT_SIZE="-0.04368837714972551" NO="2" P_CHI2="0.6643827291680249" P_Z="0.33394662311100387" STUDIES="2" TAU2="0.0" TOTAL_1="263" TOTAL_2="263" WEIGHT="26.120565166916787" Z="0.9661950068841761">
<NAME>Radiotherapy</NAME>
<IPD_DATA CI_END="1.1160354478495476" CI_START="0.6945930149889928" EFFECT_SIZE="0.8804489914562956" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="142" LOG_CI_END="0.04767798901102595" LOG_CI_START="-0.1582695883834331" LOG_EFFECT_SIZE="-0.05529579968620359" ORDER="1" O_E="-8.7" SE="0.12097462641845494" STUDY_ID="STD-MRC_x002f_EORTC-1999" TOTAL_1="206" TOTAL_2="207" VAR="68.33" WEIGHT="19.347622957782374"/>
<IPD_DATA CI_END="1.4571710896634902" CI_START="0.6537750613452302" EFFECT_SIZE="0.9760441171049822" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="47" LOG_CI_END="0.16351054623432573" LOG_CI_START="-0.18457164987177438" LOG_EFFECT_SIZE="-0.01053055181872434" ORDER="2" O_E="-0.58" SE="0.20446520502738266" STUDY_ID="STD-Sengelov-2002" TOTAL_1="57" TOTAL_2="56" VAR="23.92" WEIGHT="6.7729422091344125"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="2.675577428219479E-4" CI_END="1.0194440216345428" CI_START="0.5785420568818538" DF="1" EFFECT_SIZE="0.7679786723290938" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="106" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.008363383363122819" LOG_CI_START="-0.23766506470218313" LOG_EFFECT_SIZE="-0.1146508406695301" NO="3" P_CHI2="0.9869494307637902" P_Z="0.06774313281548318" STUDIES="2" TAU2="0.0" TOTAL_1="189" TOTAL_2="198" WEIGHT="13.5572104085851" Z="1.826711669130813">
<NAME>Radiotherapy + cystectomy</NAME>
<IPD_DATA CI_END="1.0569803434329326" CI_START="0.5593483719016095" EFFECT_SIZE="0.7689084693454838" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="84" LOG_CI_END="0.024066910847645253" LOG_CI_START="-0.25231762168451516" LOG_EFFECT_SIZE="-0.11412535541843495" ORDER="1" O_E="-9.97" SE="0.16234964253489187" STUDY_ID="STD-Malmstrom-1996" TOTAL_1="151" TOTAL_2="160" VAR="37.94" WEIGHT="10.742701814989948"/>
<IPD_DATA CI_END="1.4234039581795046" CI_START="0.41054304456836493" EFFECT_SIZE="0.7644400530072162" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.1533281691719008" LOG_CI_START="-0.386641301301012" LOG_EFFECT_SIZE="-0.11665656606455556" ORDER="2" O_E="-2.67" SE="0.3171807398477756" STUDY_ID="STD-MRC_x002f_EORTC-1999" TOTAL_1="38" TOTAL_2="38" VAR="9.94" WEIGHT="2.8145085935951526"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="17.04866116004272" CI_END="0.8855467558069487" CI_START="0.7370011740535218" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="0.8078669436912298" ESTIMABLE="YES" EVENTS_1="875" EVENTS_2="972" I2="47.20993094112588" I2_Q="80.3419077665962" ID="CMP-001.03" LOG_CI_END="-0.052788503640609226" LOG_CI_START="-0.13253182030301114" LOG_EFFECT_SIZE="-0.09266016197181016" NO="3" P_CHI2="0.047959434974483184" P_Q="0.02410639788344593" P_Z="5.241573443189468E-6" Q="5.086963618477487" SCALE="10.0" SORT_BY="USER" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1419" TOTAL_2="1427" WEIGHT="100.0" Z="4.554879026044405">
<NAME>Overall disease-free survival by chemotherapy type</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="1.0212733471597049" CI_END="1.550538581799906" CI_START="0.833173006828541" DF="1" EFFECT_SIZE="1.1366032255813325" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="85" I2="2.0830218686181157" ID="CMP-001.03.01" LOG_CI_END="0.19048257718691025" LOG_CI_START="-0.07926480878587663" LOG_EFFECT_SIZE="0.05560888420051683" NO="1" P_CHI2="0.31221745211850227" P_Z="0.4190331148764316" STUDIES="2" TAU2="0.0" TOTAL_1="103" TOTAL_2="114" WEIGHT="8.739248727400387" Z="0.8080998439367038">
<NAME>Single agent cisplatin trials</NAME>
<IPD_DATA CI_END="1.499875599533269" CI_START="0.6313069606877213" EFFECT_SIZE="0.9730785714170371" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="39" LOG_CI_END="0.1760552399378973" LOG_CI_START="-0.199759422186028" LOG_EFFECT_SIZE="-0.011852091124065364" ORDER="1" O_E="-0.56" SE="0.22075539284417398" STUDY_ID="STD-Martinez-1995" TOTAL_1="62" TOTAL_2="59" VAR="20.52" WEIGHT="4.502369668246446"/>
<IPD_DATA CI_END="2.0941234576930774" CI_START="0.8582066870339302" EFFECT_SIZE="1.3405934338444354" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="46" LOG_CI_END="0.32100228164766753" LOG_CI_START="-0.06640810582452869" LOG_EFFECT_SIZE="0.1272970879115694" ORDER="2" O_E="5.66" SE="0.22756677931351457" STUDY_ID="STD-Raghavan-1991" TOTAL_1="41" TOTAL_2="55" VAR="19.31" WEIGHT="4.2368790591539405"/>
</IPD_SUBGROUP>
<IPD_SUBGROUP CHI2="10.940424194405523" CI_END="0.8607529135799765" CI_START="0.7102386458105262" DF="7" EFFECT_SIZE="0.7818823336784809" ESTIMABLE="YES" EVENTS_1="794" EVENTS_2="887" I2="36.01710614128191" ID="CMP-001.03.02" LOG_CI_END="-0.06512149856861" LOG_CI_START="-0.14859570037341768" LOG_EFFECT_SIZE="-0.10685859947101385" NO="2" P_CHI2="0.14123905411297766" P_Z="5.219763526884763E-7" STUDIES="8" TAU2="0.0" TOTAL_1="1316" TOTAL_2="1313" WEIGHT="91.2607512725996" Z="5.018053527275909">
<NAME>Platinum-based combination trials</NAME>
<IPD_DATA CI_END="0.8362223791963953" CI_START="0.4011109349211528" EFFECT_SIZE="0.5791527780486396" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="69" LOG_CI_END="-0.07767821393048639" LOG_CI_START="-0.3967354982996202" LOG_EFFECT_SIZE="-0.23720685611505332" ORDER="1" O_E="-15.55" SE="0.1874158281974584" STUDY_ID="STD-Abol_x002d_Enein-1997" TOTAL_1="96" TOTAL_2="100" VAR="28.47" WEIGHT="6.246708794102159"/>
<IPD_DATA CI_END="1.0324990795257387" CI_START="0.5528476236896566" EFFECT_SIZE="0.7555227743606161" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="87" LOG_CI_END="0.013889673154520372" LOG_CI_START="-0.2573945527996143" LOG_EFFECT_SIZE="-0.12175243982254695" ORDER="2" O_E="-11.04" SE="0.15935369720403486" STUDY_ID="STD-Malmstrom-1996" TOTAL_1="151" TOTAL_2="160" VAR="39.38" WEIGHT="8.640512550465159"/>
<IPD_DATA CI_END="1.4639093684853672" CI_START="0.6352905249412066" EFFECT_SIZE="0.9643690948860915" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="42" LOG_CI_END="0.16551419012053506" LOG_CI_START="-0.1970276219139683" LOG_EFFECT_SIZE="-0.015756715896716622" ORDER="3" O_E="-0.8" SE="0.21295885499997996" STUDY_ID="STD-Cortesi-_x0028_unpub_x0029_" TOTAL_1="82" TOTAL_2="71" VAR="22.05" WEIGHT="4.838072669826225"/>
<IPD_DATA CI_END="0.7725170074814162" CI_START="0.452113266474068" EFFECT_SIZE="0.5909866222336975" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="121" LOG_CI_END="-0.11209195051280693" LOG_CI_START="-0.3447527491657725" LOG_EFFECT_SIZE="-0.22842234983928977" ORDER="4" O_E="-28.16" SE="0.13666610481827954" STUDY_ID="STD-Grossman-2003" TOTAL_1="158" TOTAL_2="159" VAR="53.54" WEIGHT="11.747410918027033"/>
<IPD_DATA CI_END="1.3491919771139356" CI_START="0.6486647815050277" EFFECT_SIZE="0.9355069850316178" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="61" LOG_CI_END="0.13007375001975333" LOG_CI_START="-0.18797968094018697" LOG_EFFECT_SIZE="-0.028952965460216768" ORDER="5" O_E="-1.91" SE="0.1868261597357436" STUDY_ID="STD-Bassi-1999" TOTAL_1="102" TOTAL_2="104" VAR="28.65" WEIGHT="6.286203264876251"/>
<IPD_DATA CI_END="0.9565558412254836" CI_START="0.7053339154309088" EFFECT_SIZE="0.8213959318257409" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="345" LOG_CI_END="-0.019289671921885652" LOG_CI_START="-0.15160523294206155" LOG_EFFECT_SIZE="-0.08544745243197359" ORDER="6" O_E="-32.57" SE="0.07772281551584166" STUDY_ID="STD-MRC_x002f_EORTC-1999" TOTAL_1="491" TOTAL_2="485" VAR="165.54" WEIGHT="36.321748288572934"/>
<IPD_DATA CI_END="1.3986916877360729" CI_START="0.7027140317130433" EFFECT_SIZE="0.9914031848912614" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="61" LOG_CI_END="0.14572199392615154" LOG_CI_START="-0.15322137443388575" LOG_EFFECT_SIZE="-0.0037496902538671113" ORDER="7" O_E="-0.28" SE="0.17560081436822508" STUDY_ID="STD-Sengelov-2002" TOTAL_1="78" TOTAL_2="75" VAR="32.43" WEIGHT="7.115587151132175"/>
<IPD_DATA CI_END="1.027498509826366" CI_START="0.5759968707798286" EFFECT_SIZE="0.7693087328185765" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="101" LOG_CI_END="0.011781200694427394" LOG_CI_START="-0.23957987596349734" LOG_EFFECT_SIZE="-0.11389933763453494" ORDER="8" O_E="-12.03" SE="0.14765074068626158" STUDY_ID="STD-Sherif-2002" TOTAL_1="158" TOTAL_2="159" VAR="45.87" WEIGHT="10.064507635597684"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Concurrent CTRT + local treatment vs local treatment alone</NAME>
<IPD_OUTCOME CHI2="0.0" CI_END="1.1844884991724078" CI_START="0.4932330134944094" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.7643486324291272" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.07353084828359702" LOG_CI_START="-0.30694786253329687" LOG_EFFECT_SIZE="-0.1167085071248499" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.22920724786775926" Q="0.0" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="49" WEIGHT="100.00000000000001" Z="1.2024035203600436">
<NAME>Survival</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.1844884991724078" CI_START="0.4932330134944094" EFFECT_SIZE="0.7643486324291272" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="42" LOG_CI_END="0.07353084828359702" LOG_CI_START="-0.30694786253329687" LOG_EFFECT_SIZE="-0.1167085071248499" ORDER="1" O_E="-5.38" SE="0.2234950781338371" STUDY_ID="STD-Coppin-1996" TOTAL_1="53" TOTAL_2="49" VAR="20.02" WEIGHT="100.00000000000001"/>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Neoadjuvant CT + Local Treatment + Adjuvant CT vs Local Treatment alone</NAME>
<IPD_OUTCOME CHI2="0.0" CI_END="1.0528095180749364" CI_START="0.683895128264142" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.8485347962232122" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="173" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.022349802588970076" LOG_CI_START="-0.16501048995835224" LOG_EFFECT_SIZE="-0.07133034368469107" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.13560367221244013" Q="0.0" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="198" WEIGHT="100.0" Z="1.4923642862219324">
<NAME>Survival</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Peto Odds Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.0528095180749364" CI_START="0.683895128264142" EFFECT_SIZE="0.8485347962232122" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="173" LOG_CI_END="0.022349802588970076" LOG_CI_START="-0.16501048995835224" LOG_EFFECT_SIZE="-0.07133034368469107" ORDER="1" O_E="-13.56" SE="0.11005636329070297" STUDY_ID="STD-Shearer-1988" TOTAL_1="200" TOTAL_2="198" VAR="82.56" WEIGHT="100.0"/>
</IPD_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Overall survival in the cisplatin-based combination chemotherapy trials</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>